News Column

IDENIX PHARMACEUTICALS INC FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders

June 6, 2014



Item 5.07 Submission of Matters to a Vote of Security Holders

Idenix Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders on June 5, 2014. At the annual meeting, the stockholders elected all of the nominees of the Company's Board of Directors for a term of one year and until his or her successor is duly elected and qualified. In addition, at the annual meeting, the stockholders (i) approved the Company's 2014 Employee Stock Purchase Plan and the reservation of 2,000,000 shares for future issuance thereof, (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year ending December 31, 2014, and (iii) approved on an advisory basis the compensation of the Company's named executive officers as disclosed in the proxy statement for the 2014 Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and narrative disclosure.

The final voting results are set forth below:

a) The following nominees for director were elected as follows:

Nominee For Withheld Non-Votes Wayne T. Hockmeyer, Ph.D. 120,564,194 2,139,355 13,040,775 Thomas R. Hodgson 120,594,787 2,108,762 13,040,775 Tamar D. Howson 120,355,081 2,348,468 13,040,775 Denise Pollard-Knight, Ph.D. 120,564,094 2,139,455 13,040,775 Ronald C. Renaud, Jr. 122,631,265 72,284 13,040,775 Charles Rowland, Jr. 120,602,491 2,101,058 13,040,775 Michael Wyzga 120,605,177 2,098,372 13,040,775



b) The Company's 2014 Employee Stock Purchase Plan and the reservation of 2,000,000 shares for future issuance thereof was approved as follows:

For: 122,447,648 Against: 214,819 Abstain: 41,082 Non Votes: 13,040,775



c) The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm the current fiscal year ending December 31, 2014 was approved as follows:

For: 135,532,642 Against: 122,421 Abstain: 89,261



--------------------------------------------------------------------------------

d) The compensation of the Company's named executive officers was approved on an advisory basis as disclosed in the proxy statement for the 2014 Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and narrative disclosure. The final voting results were as follows:

For: 120,430,366 Against: 2,233,538 Abstain: 39,645 Non Votes: 13,040,775



--------------------------------------------------------------------------------


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters